How to Manage Side Effects of Radioactive Peptide Therapy for Neuroendocrine Tumors

This review provides a comprehensive guide to managing the toxicities of peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE in neuroendocrine tumor patients. Toxicities can be acute, subacute, or long-term, affecting multiple organ systems. Key management topics include screening for clonal hematopoiesis before treatment (a risk factor for blood cancers), steroid prophylaxis to prevent carcinoid crisis and bowel obstruction, and evidence-based monitoring strategies for kidney and bone marrow toxicity.

Narrative review of published literature on PRRT toxicities, summarizing evidence from clinical trials (NETTER-1, NETTER-2) and clinical experience with monitoring, prevention, and management strategies.

As PRRT use grows with rising neuroendocrine tumor incidence, more clinicians need practical guidance on managing its side effects. This review consolidates current evidence on toxicity management into a single resource, addressing emerging concerns like pre-treatment clonal hematopoiesis screening that could prevent rare but serious blood cancers.

PRRT represents one of the most successful applications of peptide-based targeted therapy — using somatostatin analog peptides as guided missiles to deliver radiation to tumors. As it moves from specialized centers to broader oncology practice, standardizing toxicity management becomes critical. This review also reflects the growing recognition that pre-treatment genomic screening (for clonal hematopoiesis) may help identify patients at higher risk for therapy-related blood cancers.

Narrative review without systematic search methodology or meta-analysis. Management recommendations are based on available evidence and clinical experience, which may be limited for rare toxicities. The rapidly evolving nature of PRRT practice means some recommendations may change quickly.